Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development

With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.